Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Schilling

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
International Journal of Alzheimer'S Disease|September 24, 2010
Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse ModelAn Tanghe, Annelies Termont, Pascal Merchiers, et al.
Scientific Reports|February 26, 2020
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activationThore Hettmann, Stephen D Gillies, Martin Kleinschmidt, et al.
International Journal of Molecular Sciences|June 2, 2021
Structure and Dynamics of Meprin β in Complex with a Hydroxamate-Based InhibitorMiriam Linnert, Claudia Fritz, Christian Jäger, et al.
Journal of Neurochemistry|March 2, 2012
N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiationDagmar Schlenzig, Raik Rönicke, Holger Cynis, et al.
Acta Neuropathologica|April 13, 2010
Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's diseaseMarkus Morawski, Maike Hartlage-Rübsamen, Carsten Jäger, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 27, 2024
Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosisJanett Köppen, Martin Kleinschmidt, Markus Morawski, et al.
Neurobiology of Aging|September 28, 2011
No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's diseaseAntje Hillmann, Stefanie Hahn, Stephan Schilling, et al.
The Journal of Biological Chemistry|June 18, 2017
Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapyAnke Piechotta, Christoph Parthier, Martin Kleinschmidt, et al.
Biomolecules|March 25, 2022
Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD MiceKathrin Gnoth, Stefanie Geissler, Julia Feldhaus, et al.
Acta Neuropathologica|February 9, 2011
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanismsMaike Hartlage-Rübsamen, Markus Morawski, Alexander Waniek, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
International Journal of Alzheimer'S Disease|September 24, 2010
Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse ModelAn Tanghe, Annelies Termont, Pascal Merchiers, et al.
Scientific Reports|February 26, 2020
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activationThore Hettmann, Stephen D Gillies, Martin Kleinschmidt, et al.
International Journal of Molecular Sciences|June 2, 2021
Structure and Dynamics of Meprin β in Complex with a Hydroxamate-Based InhibitorMiriam Linnert, Claudia Fritz, Christian Jäger, et al.
Journal of Neurochemistry|March 2, 2012
N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiationDagmar Schlenzig, Raik Rönicke, Holger Cynis, et al.
Acta Neuropathologica|April 13, 2010
Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's diseaseMarkus Morawski, Maike Hartlage-Rübsamen, Carsten Jäger, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 27, 2024
Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosisJanett Köppen, Martin Kleinschmidt, Markus Morawski, et al.
Neurobiology of Aging|September 28, 2011
No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's diseaseAntje Hillmann, Stefanie Hahn, Stephan Schilling, et al.
The Journal of Biological Chemistry|June 18, 2017
Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapyAnke Piechotta, Christoph Parthier, Martin Kleinschmidt, et al.
Biomolecules|March 25, 2022
Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD MiceKathrin Gnoth, Stefanie Geissler, Julia Feldhaus, et al.
Acta Neuropathologica|February 9, 2011
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanismsMaike Hartlage-Rübsamen, Markus Morawski, Alexander Waniek, et al.
Pageof 10